Detalhe da pesquisa
1.
Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.
N Engl J Med
; 385(1): 46-58, 2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34192431
2.
Daratumumab plus bortezomib, cyclophosphamide, and dexamethasone in Asian patients with newly diagnosed AL amyloidosis: subgroup analysis of ANDROMEDA.
Ann Hematol
; 102(4): 863-876, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-36862168
3.
Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma.
J Oncol Pharm Pract
; 29(5): 1172-1177, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-36067063
4.
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial.
Lancet Oncol
; 22(11): 1582-1596, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34655533
5.
Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab: part 3 of the open-label, multicenter, phase 1b PAVO study.
Leuk Lymphoma
; 64(2): 468-472, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36593729
6.
A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease.
Oncotarget
; 6(30): 30408-19, 2015 Oct 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-26327301
7.
A phase I/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors.
Clin Cancer Res
; 20(8): 2192-204, 2014 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-24563479
8.
A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors.
Cancer Chemother Pharmacol
; 71(4): 1041-50, 2013 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-23385782